Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

effort, Amicus continues to conduct preclinical studies in Parkinson's disease and is investing in new research aimed at evaluating disease targets for other neurodegenerative and genetic disorders. In September 2008, the Company entered into a lease for laboratory space for a small scale research facility in San Diego, Calif. This facility will complement Amicus' core research and development activities in New Jersey, while allowing closer access to the significant scientific and biotechnology resources in the San Diego community.

Shire Collaboration:

In November 2007, Amicus entered into a strategic collaboration with Shire Human Genetic Therapies, Inc., a wholly-owned subsidiary of Shire plc, to jointly develop Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders, Amigal, Plicera and AT2220. In this collaboration, valued at up to $440 million including an up front payment and success based clinical and sales milestones and excluding royalties and cost sharing, Shire reimburses world-wide development costs on a 50/50 basis, and in return Shire received rights to commercialize these products outside of the U.S. while Amicus retains all rights to commercialize these products in the U.S. In addition, Amicus leads development operations through the end of Phase 2 clinical trials. The companies then share responsibility for Phase 3 clinical trial development leveraging Shire's significant ex-U.S. regulatory and clinical experience as well as its commercial infrastructure.

Additional Financial Results & Notes

On a reported basis, the net loss attributable to common stockholders for the three months ended September 30, 2008, was $8.2 million as compared to $10.3 million for the same period in 2007. On a non-GAAP basis, the net loss for the three months ended September 30, 2008, was $6.6 million as compared to $9.2 million in the same period in 2007.

Amicus recorded revenue during the third quarter of 20
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 2015 Global futurist and keynote ... ask his audiences if they are ready for ... solar cells, fuel cells, rapid health care diagnostic ... storage technology, driverless cars, artificial intelligence masquerading as ... online education. , While the majority of ...
(Date:5/28/2015)... Clinerion, an eClinical technology ... the Alliance for Clinical Research Excellence and ... operating in the public interest and dedicated ... quality, safety, integrity and operational effectiveness in ... pleased to announce their partnership for accelerating ...
(Date:5/27/2015)... 26, 2015 Research and Markets( http://www.researchandmarkets.com/research/8nqqdw/global_breast ... "Global Breast Cancer Monoclonal Antibodies Market Outlook 2020" ... Roche seems to dominate the breast cancer monoclonal ... buster molecule, Herceptin has been able to dominate ... that breast cancer cells become recalcitrant and relapsed ...
(Date:5/27/2015)... Israel , May 27, 2015  Tikcro Technologies ... quarter ended March 31, 2015. ... quarter, we continued pre-clinical work to generate functional specific ... an early stage, we are encouraged by the development ... field as new antibodies which modulate immune checkpoints gain ...
Breaking Biology Technology:Futurist Jack Uldrich to Deliver 4 Keynote Addresses in June 2Clinerion and ACRES Partner on Patient Recruitment and Risk-Based Quality Management 2Clinerion and ACRES Partner on Patient Recruitment and Risk-Based Quality Management 3Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 2Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 3Tikcro Technologies Reports First Quarter 2015 Results 2Tikcro Technologies Reports First Quarter 2015 Results 3
... Technologies,Corporation,s (OTC Bulletin Board: CNVT) holding BIOREM announced the,receipt ... China for a,Biofiltair odor control system. This order for ... (Cdn) and is the third order,received from China over ... our technology was accepted on these projects,",said Peter Bruijns, ...
... RDEA ) today announced that its President and ... the "In Search of the,Next HIV Treatment" panel discussion ... December 12, 2007 at 1:30 p.m. (ET) at,the Westin ... audio webcast of the,presentation and panel discussion will be ...
... North America with this Elevated Partner ... ... System,Integrator, today announced it has achieved Oracle Certified Advantage,Partner status in the ... level in the Oracle PartnerNetwork -- BIAS had,to demonstrate superior product knowledge ...
Cached Biology Technology:CVF Technologies Corporation's Holding - BIOREM Announces 3rd Order from China 2Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference 2Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference 3BIAS Achieves Certified Advantage Partner Level in Oracle PartnerNetwork 2BIAS Achieves Certified Advantage Partner Level in Oracle PartnerNetwork 3
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, reminds investors and media that  Mr. David Tunnell ... SECURE CONNEXIONS AMERICA 2015, held in Washington DC ... conference is organized into a series of nine session tracks. ... Fraud: Where is the Trust in Cyberspace? and will ...
(Date:4/20/2015)... April 20, 2015 Huntington Memorial Hospital is ... implant a new miniaturized, wireless monitoring sensor to manage ... first and only FDA-approved heart failure monitoring device that ... used by physicians to manage heart failure. ... implanted in the pulmonary artery (PA) during a non-surgical ...
(Date:4/13/2015)... YORK , April 13, 2015 ... by TechSci Research, "Global Biometrics Market Forecast & Opportunities, ... register a CAGR of around 14% till 2020. ... governments for large scale implementation and review of ... and launch of new products with greater efficiency, ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... visiting researcher from Sweden in the Indiana University College of ... in culturing, characterizing and formally naming a new class of ... from environmental samples. ,Structures on Roots ... Soil Clone Group 1 (SCG1), has now been found in ...
... New research led by scientists from Imperial College London explains ... phase, of symptoms several hours after exposure to allergens. The ... to better treatments for the disease. An estimated 300 ... Symptoms are commonly triggered by allergens in the environment, such ...
... A thriving undersea wildlife park tucked away near the southern ... world,s most robust marine reserve in the world, according to ... Oceanography at UC San Diego. Results of a ... the Public Library of Science (PLoS) ONE journal, ...
Cached Biology News:Visiting researcher at IU leads international team in formal identification of new fungi class 2Visiting researcher at IU leads international team in formal identification of new fungi class 3Study sheds light on late phase of asthma attacks 2Hidden Baja undersea park is the world's most robust marine reserve 2Hidden Baja undersea park is the world's most robust marine reserve 3
... four-bay DNA Engine Tetrad 2 thermal ... Alpha units (sample-holder, heat-pump assemblies), which ... vessels. A Pentium-class computer drives an ... block, sample, and lid temperatures. Peltier ...
Printer paper for Model 680 series readers is used with the thermal printers of the Model 680 and Model 680 XR microplate readers. Supplied as 2 rolls....
... multi-cell is for 2-D separations. The cell has ... PROTEAN II xi multi-cell can be customized for ... plates, and cooling system. The PROTEAN II xi ... II XL multi-cell for a wider format that ...
... This depletion cocktail is tailored ... from suspensions of rat spleen ... the StemSep (or compatible 0.5 ... The T cell content of ...
Biology Products: